Taysha Gene Therapies (NASDAQ:TSHA) Earns Buy Rating from Needham & Company LLC

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a note issued to investors on Monday,Benzinga reports. They currently have a $6.00 price objective on the stock. Needham & Company LLC’s price target would indicate a potential upside of 212.50% from the stock’s current price.

TSHA has been the subject of a number of other reports. Canaccord Genuity Group lifted their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, November 15th. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Finally, Chardan Capital restated a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Taysha Gene Therapies currently has an average rating of “Buy” and an average target price of $6.63.

Taysha Gene Therapies Price Performance

Shares of Taysha Gene Therapies stock opened at $1.92 on Monday. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $393.49 million, a price-to-earnings ratio of 3.05 and a beta of 0.95. Taysha Gene Therapies has a twelve month low of $1.19 and a twelve month high of $4.32. The company has a 50-day simple moving average of $2.10 and a two-hundred day simple moving average of $2.16.

Institutional Trading of Taysha Gene Therapies

Institutional investors and hedge funds have recently modified their holdings of the business. Creative Planning acquired a new position in Taysha Gene Therapies during the third quarter worth about $28,000. Principal Financial Group Inc. bought a new stake in shares of Taysha Gene Therapies during the 2nd quarter valued at approximately $48,000. China Universal Asset Management Co. Ltd. increased its position in Taysha Gene Therapies by 79.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock worth $79,000 after purchasing an additional 17,446 shares in the last quarter. Intech Investment Management LLC bought a new position in Taysha Gene Therapies in the 3rd quarter valued at approximately $85,000. Finally, Scientech Research LLC acquired a new stake in Taysha Gene Therapies in the second quarter valued at approximately $97,000. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.